+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Type 2 Diabetes Mellitus- Pipeline Insight, 2022

  • PDF Icon

    Drug Pipelines

  • 100 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 5552794
The publisher’s, “Type 2 Diabetes Mellitus- Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 2 Diabetes mellitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Type 2 Diabetes Mellitus Understanding


Type 2 Diabetes Mellitus: Overview

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes. Type 2 diabetes mellitus (T2DM) accounts for around 90% of all cases of diabetes. In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Type 2 diabetes primarily occurs as a result of obesity and lack of exercise. Some people are more genetically at risk than others. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to type 1 diabetes and gestational diabetes. Diagnosis of diabetes is by blood tests such as fasting plasma glucose, oral glucose tolerance test, or glycated hemoglobin (A1C). Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.

"Type 2 Diabetes Mellitus- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 2 Diabetes Mellitus pipeline landscape is provided which includes the disease overview and Type 2 Diabetes Mellitus treatment guidelines. The assessment part of the report embraces, in depth Type 2 Diabetes Mellitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 2 Diabetes Mellitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Type 2 Diabetes mellitus R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Type 2 Diabetes mellitus Emerging Drugs Chapters

This segment of the Type 2 Diabetes mellitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type 2 Diabetes mellitus Emerging Drugs

Sotagliflozin: Lexicon Pharmaceuticals

Sotagliflozin: Lexicon Pharmaceuticalsotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of heart failure and type 1 and type 2 diabetes. The scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type 1, or SGLT1, and sodium-glucose cotransporter type 2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is in the phase 3 stage of development to treat Type 2 diabetes mellitus.

ORMD0801: Oramed Pharmaceuticals

ORMD0801: Oramed Pharmaceuticalsramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin brings with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.ORMD0801 is in the phase 3 stage of development to treat Type 2 diabetes mellitus.

LY3209590-Eli lily and Company

LY3209590-Eli lily and Company Y3209590 "Basal insulin-Fc" is a large molecule comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is in Phase 2 stage of development for the treatment of Type 2 diabetes.

HM12460A: Hanmi Pharmaceuticals

HM12460A: Hanmi Pharmaceuticalshe novel basal insulin HM12460A consists of an insulin analog (Insulin 115)conjugated to the human aglycosylated FC fragment via a small PEG linker and is developed for once-weekly administration HM12460A displays substantially prolonged pharmacokinetic and pharmacodynamic profile ,No increased mitogenic potency compared to regular insulin .It showed similar metabolic potency compared to regular insulin after long-term stimulation , decreased insulin receptor downregulation and it showed improved insulin signaling under chronic conditions.It is in Phase1 stage of development for the treatment of Type 2 diabetes.

HM14220:Hanmi Pharmaceuticals

HM14220:Hanmi PharmaceuticalsM14220 is a combination of a long-acting insulin analog and a long-acting exendin-4 analog; Targeting once weekly administration. It is in the pre-clinical stage of development for the treatment of Type 2 Diabetes.

Type 2 Diabetes mellitus: Therapeutic Assessment


This segment of the report provides insights about the different Type 2 Diabetes mellitus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Type 2 Diabetes mellitus

There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.

Phases

The publisher’s report covers around 100+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Type 2 Diabetes mellitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 2 Diabetes mellitus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 2 Diabetes mellitus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 2 Diabetes mellitus drugs.

Type 2 Diabetes mellitus Report Insights

  • Type 2 Diabetes mellitus Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Type 2 Diabetes mellitus Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Type 2 Diabetes mellitus drugs?
  • How many Type 2 Diabetes mellitus drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 2 Diabetes mellitus?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 2 Diabetes mellitus therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Type 2 Diabetes mellitus and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Hanmi Pharmaceuticals
  • Sanofi
  • Eli lily and Company
  • AstraZeneca
  • NovoNordisk
  • Noxxon Pharma AG
  • Oramed Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Daiichi Sankyo Company
  • Halozyme Therapeutics
  • Saniona
  • Novartis
  • Pfizer
  • Merck Sharp & Dohme Corp.
  • Mylan
  • Nordic Bioscience A/S
  • KeyBioscience AG
  • Adocia
  • Jiangsu Hengrui Medicine
  • Bristol myers Suibb
  • Phenomix
  • Forest Laboratories
  • ACADIA Pharmaceuticals
  • Hanmi Pharmaceuticals
  • Cytogel
  • Ligand Pharmaceuticals
  • Arthritis Innovation Corporation
  • Astellas Pharma
  • IItoo Pharma
  • Medspace Inc.
  • Oramed Ltd.
  • Flexion Therapeutics
  • Integrium
  • AbbVie

Key Products

  • ORMD0801
  • HumalogU-100
  • Sotagliflozin
  • Exenatide
  • Topiramate
  • LY3209590
  • HM12460A
  • HM14220
  • Tesofensine/Metoprolol
  • Ruboxistaurin Mesylate
  • BMS-816336
  • Atrasentan
  • Inhaled Human Insulin
  • Human regular U-500 insulin
  • Humalog
  • Insulin Glargine
  • Tirzepatide
  • Oxyntomodulin

Table of Contents

Introduction

Executive Summary

Type 2 Diabetes mellitus: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management


Pipeline Therapeutics
  • Comparative Analysis


Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type


Type 2 Diabetes mellitus - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
  • Sotagliflozin: Lexicon Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities


Mid Stage Products (Phase II)
  • Comparative Analysis
  • LY3209590: Eli lily and Company
  • Product Description
  • Research and Development
  • Product Development Activities


Early Stage Products (Phase I)
  • Comparative Analysis
  • HM12460A: Hanmi Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities


Preclinical and Discovery Stage Products
  • Comparative Analysis
  • HM14220: Hanmi Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities


Inactive Products
  • Comparative Analysis
  • Type 2 Diabetes mellitus- Key Companies
  • Type 2 Diabetes mellitus- Key Products
  • Type 2 Diabetes mellitus - Unmet Needs
  • Type 2 Diabetes mellitus - Market Drivers and Barriers
  • Type 2 Diabetes mellitus - Future Perspectives and Conclusion
  • Type 2 Diabetes mellitus Analyst Views
  • Type 2 Diabetes mellitus Key Companies


AppendixList of Tables
Table 1 Total Products for Type 2 Diabetes mellitus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Type 2 Diabetes mellitus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Hanmi Pharmaceuticals
  • Sanofi
  • Eli lily and Company
  • AstraZeneca
  • NovoNordisk
  • Noxxon Pharma AG
  • Oramed Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Daiichi Sankyo Company
  • Halozyme Therapeutics
  • Saniona
  • Novartis
  • Pfizer
  • Merck Sharp & Dohme Corp.
  • Mylan
  • Nordic Bioscience A/S
  • KeyBioscience AG
  • Adocia
  • Jiangsu Hengrui Medicine
  • Bristol myers Suibb
  • Phenomix
  • Forest Laboratories
  • ACADIA Pharmaceuticals
  • Hanmi Pharmaceuticals
  • Cytogel
  • Ligand Pharmaceuticals
  • Arthritis Innovation Corporation
  • Astellas Pharma
  • IItoo Pharma
  • Medspace Inc.
  • Oramed Ltd.
  • Flexion Therapeutics
  • Integrium
  • AbbVie